Certified according to
DIN EN ISO 13485:2016

DaraEx and DaraEx plus

DaraEx – anti-CD38 antibody neutralizing agent

Antibody based drugs can disturb serological blood group testing since the examined antigens can be masked by the therapeutic antibodies. An anti-CD38 antibody for treatment of multiple myeloma shows a strong interference in the indirect antiglobulin test (IAT) where most of the reactions turn to unspecifically (wrong) positive. The time consuming standard technique using Dithiothreitol (DTT) counteracts the interference but has major drawbacks like destruction of Kel antigens or hemolysis. The imusyn DaraEx compound inhibits the agglutination effect of anti-CD38 in IAT without side effects.

Your contact – worldwide
Dr. Sabrina König
Phone: +49 6173 6079 30
E-mail: s.koenig@inno-train.de

Your contact – USA & Canada
Molly Suba
Phone: +1 315 210 4017
E-mail: m.suba@innotrain.org

Downloads

Flyer DaraEx & DaraEx plus

Improved DaraEx version is now available as RUO and CE-IVD

We are happy to announce that the anti-CD38 antibody neutralizing agent DaraEx has now an improved functionality by changing the chemistry from a F(ab)2 fragment to a Fab fragment. The new uniform express protocol does not need a pre-incubation of the test cells with DaraEx anymore. Instead DaraEx can be added directly on the gel card without any delay in the indirect antiglobulin test (IAT).

Method

No preincubation of test cells with DaraEx / DaraEx plus
Cells can be used for indirect antiglobulin test with conventional gel card systems

Publications

Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform? Habicht CP,Ridders M, Grueger D, Adolph S, Immenschuh S, Schneeweiss C. Transfusion. 2023 Jan 27. doi: 10.1111/trf.17253. Online ahead of print. PMID: 36707937
Effective Neutralization of Daratumumab Effects on Pre-Transfusion Testing: a Method Modification. Feldmann A, Duek AM, Mandel-Benando M, Cohen LA, Feldman DR, Leiba M. Clin. Lab.2022 Sep 1;68(9).doi: 10.7754/Clin.Lab.2022.211243.PMID: 36125160

Advantages of DaraEx

R

Quick and simple procedure

R

Specific inhibition of anti-CD38 reactivity without affecting other antigens or alloantibody reactions

R

No side effects like destruction of blood group antigens or hemolysis as described for the standard DTT treatment

R

No need for expensive anti-idiotypic antibodies or soluble CD38 protein for blocking anti-CD38

DaraEx / DaraEx plus

Item number	Name	Description
004 020 001	DaraEx (RUO)	300 µl vial
004 020 004	DaraEx plus (CE-IVD)	300 µl vial
004 020 005	Dara-FC (function control)	450 µl vial

Do you have any questions?

We will be happy to help you!
Call us: +49 6173 6079 30

or write a message here